Immuno-Oncology in Biliary Tract Cancers

Videos — December 22, 2021

Featuring:

Vaibhav Sahai, MBBS, MS
Associate Professor
Section Head GI Oncology
Division of Hematology and Oncology
University of Michigan
Ann Arbor, MI

Dr V. Sahai discusses how to move forward with immune-oncology approaches in biliary tract cancers, including key investigations that are needed to improve outcomes with immunotherapy in CCA.

Related Items

CCA Summit Live from ASCO 2023
By Renuka V. Iyer, MD; Vaibhav Sahai, MBBS, MS
Videos
On June 4, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO).
A Global Perspective on CCA
By Virote Sriuranpong, MD, PhD
Videos
Dr Virote Sriuranpong provides a perspective on key issues facing Thailand and other Asian countries in the prevention, screening, and early diagnosis of CCA.
Molecular Targets in iCCA Surgical Candidates
By Keri Lunsford, MD, PhD, FACS; Alice Wei, MD, MSc, FRCSC, FACS
Videos
Drs Keri Lunsford and Alice Wei provide their perspectives on how the molecular profile of iCCA patients can help direct surgery and locoregional therapy.
Periadjuvant Therapy in iCCA
By Cristina Ferrone, MD; Shishir Kumar Maithel, MD, FACS
Videos
Dr Cristina Ferrone discusses the use of adjuvant therapy, and Dr Shishir Kumar Maithel speaks to the role of neoadjuvant therapy in patients with iCCA.
New Frontiers in Surgery for CCA
By Skye Mayo, MD, MPH, FACS; Alice Wei, MD, MSc, FRCSC, FACS
Videos
Drs Alice Wei and Skye Mayo discuss options for induction therapy prior to surgery in iCCA.
Transplantation in iCCA
By Keri Lunsford, MD, PhD, FACS; Maria B. Majella Doyle, MD, MBA, FRCSI, FACS
Videos
Drs Keri Lunsford and Maria Majella Doyle explore clinical data on neoadjuvant treatment before transplantation in patients with iCCA.
Resistance Mechanisms and Adverse Events Associated with Targeted Therapy in Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Dermatologic and ocular adverse events require appropriate and timely referral, and circulating tumor (ct) DNA analysis may not detect genomic fusions, as discussed in Session VI, “Molecularly Targeted Therapies in CCA,” at the 3rd Annual CCA Summit.
A Global Perspective on Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
Experts from around the world emphasized the global burden of cholangiocarcinoma (CCA) during a Keynote Panel, “A Global Perspective on CCA: Perspectives on Research and Treatment from the US, EU, Latin America, and Asia” at the 3rd Annual CCA Summit.
The Cholangiocarcinoma Foundation 2021 Update
By Erin Burns, PhD
December 2021, Vol 2, No 4
Stacie Lindsey, Founder and CEO, Cholangiocarcinoma Foundation (CCF), delivered a Keynote Address during the 3rd Annual CCA Summit that centered on the need to work together and to focus on the patient in the development of platform studies for patients with cholangiocarcinoma (CCA) and the subsequent analysis of data. Ms Lindsey provided updates regarding the activities of CCF and recent and future activities.
The Drug Pipeline for Cholangiocarcinoma
By Erin Burns, PhD
December 2021, Vol 2, No 4
At “The Pharma Pipeline” Roundtable during the 3rd Annual CCA Summit, experts from several pharmaceutical companies discussed recent and upcoming drugs in development for cholangiocarcinoma (CCA), emphasizing drug safety and a focus on patients.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: